

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6812612

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
WILLIAM BRUSILOW	11/23/2016
PAOLO BERNARDI	12/16/2016
RECEIVING PARTY DATA	
Name:	BURTCH PHARMACEUTICALS, LLC
Street Address:	430 RIVARD BLVD.
City:	GROSSE POINTE
State/Country:	MICHIGAN
Postal Code:	48230
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15400553
CORRESPONDENCE DATA	
Fax Number:	(248)641-0270
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2486411600
Email:	jbutler@hdp.com, mailroom@hdp.com
Correspondent Name:	HARNESS, DICKEY & PIERCE, P.L.C.
Address Line 1:	5445 CORPORATE DRIVE
Address Line 2:	SUITE 200
Address Line 4:	TROY, MICHIGAN 48098
ATTORNEY DOCKET NUMBER:	15931-000001-US-DVC
NAME OF SUBMITTER:	DAVID L. SUTER
SIGNATURE:	/DLSuter/
DATE SIGNED:	07/14/2021
Total Attachments: 3	
source=parent_Assignment_Inventors_to_Burtch_Pharma#page1.tif	
source=parent_Assignment_Inventors_to_Burtch_Pharma#page2.tif	
source=parent_Assignment_Inventors_to_Burtch_Pharma#page3.tif	

ASSIGNMENT OF PATENTS AND PATENT APPLICATIONS

This Assignment of Patents and Patent Applications is made this 2nd day of November, 2016 by William Brusilow, a Michigan resident and Paolo Bernardi, a resident of Italy (hereinafter "ASSIGNORS") to and in favor of BURTCH PHARMACEUTICALS, LLC, a Michigan limited liability company having offices at 430 Rivard Blvd., Grosse Pointe, MI 48230 (hereinafter "ASSIGNEE").

WHEREAS, ASSIGNORS are the record owners of the inventions disclosed in the issued patents and patent applications identified on Exhibit A (the "Patents and Patent Applications"); and

WHEREAS, ASSIGNEE and ASSIGNORS desire to confirm and evidence the assignment of all of ASSIGNORS's entire right, title and interest in and to the Patents and Patent Applications (and any patents that may issue therefrom) to ASSIGNEE;

NOW, THEREFORE, in consideration of good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNORS hereby acknowledge that they have assigned and transferred, and by these presents do hereby assign and transfer, unto ASSIGNEE, its successors, legal representatives, and assigns, the entire right, title, and interest throughout the world in, to, and under the Patents and Patents Applications, all patents that may be granted thereon, and all divisions, continuations, continuation-in-parts, reissues, reexaminations, renewals, and extensions thereof, or substitutions relating thereto, and all rights of priority under International Conventions and applications for Patents that may hereafter be filed for the Patents and Patent Applications in any country or countries foreign to the United States; all file histories and physical and electronic documentation, including without limitation, all invention disclosures, prosecution papers, notes, drawings, reports, flow charts, instructions, manuals, notebooks and memoranda, that directly relate to such Patents and Patent Applications; and ASSIGNORS hereby authorize and request the Commissioner of Patents of the United States, and any Official of any country foreign to the United States, whose duty it is to issue patents on applications as aforesaid, to issue all patents for said improvements and all letters patents resulting from the Patents and Patent Applications to ASSIGNEE, its successors, legal representatives, and assigns, in accordance with the terms of this Agreement.

ASSIGNORS do hereby assign, transfer, and convey to ASSIGNEE, its successors, legal representatives, and assigns all claims for damages and all remedies arising out of any violation of the rights assigned hereby that may have accrued prior to the date of assignment to ASSIGNEE, or may accrue hereafter, including, but not limited to, the right to sue for, collect, and retain damages for past infringements of the Patents and Patent Applications and any all existing or future rights which may accrue under the Patents and Patent Applications.

[Continued on Next Page]

IN WITNESS WHEREOF, ASSIGNORS have executed this Assignment of Patent and Patent Applications as of the date and year first above written.

William Brusilow
William Brusilow

Paolo Bernardi
Paolo Bernardi

STATE OF MI }
COUNTY OF Wayne } ss.

On 11/23/16, before me personally appeared William Brusilow, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument, and acknowledged to me that he executed the same in his authorized capacity on behalf of said entity.

WITNESS my hand and official seal.

[SEAL]

Signature

Meenal Sharma
Notary Signature MEENAL SHARMA
Notary Public - Michigan
Wayne County
My Commission Expires Jun 18, 2022
Acting in the County of Wayne

STATE OF Oregon }
COUNTY OF Multnomah } ss.

On Dec 16, 2016, before me personally appeared Paolo Bernardi, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument, and acknowledged to me that he executed the same in his authorized capacity on behalf of said entity.

WITNESS my hand and official seal.

[SEAL]

Keala Peters

Notary Signature

OFFICIAL STAMP
KEALA PETERS QUITUBUA
NOTARY PUBLIC - OREGON
COMMISSION NO. 853233
MY COMM. EXPIRES SEPTEMBER 18, 2020

EXHIBIT A

Assigned Patents and Patent Applications

<u>Title</u>	<u>Owner</u>	<u>Country</u>	<u>Application Number</u>	<u>Filing Date</u>	<u>Patent No.</u>	<u>Issue Date</u>
Use of methionine sulfoximine to treat acute liver failure and other diseases caused by an inflammatory cytokine response	William Brusilow and Paolo Bernardi	United States	13/136,749	August 9, 2011	8,530,515	September 10, 2013
Use of methionine sulfoximine to treat acute liver failure and other diseases caused by an inflammatory cytokine response	William Brusilow and Paolo Bernardi	United States	14/021,653	September 9, 2013	9,119,821	September 1, 2015
Use of methionine sulfoximine to treat diseases caused by an inflammatory cytokine response	William Brusilow	United States	14/833,543	August 24, 2015	Pending	